Nov 30, 2021 7:30 am EST MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin
Nov 16, 2021 7:30 am EST MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures
Nov 15, 2021 7:30 am EST MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline
Oct 26, 2021 7:00 am EDT MindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Program